Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
前日終値
$45.38
+$0.85 · +1.91%
日中の時刻はETです。市場データは遅延する場合があります。
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
日中レンジ
現在 $45.38
52週レンジ
現在 $45.38
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
94
大幅な割安
センチメント
63
強気
リスク
41
やや高いリスク
モメンタム
56
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
日中レンジ
現在 $45.38
52週レンジ
現在 $45.38
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 20.9億 USD | 19.78億 USD | 19.65億 USD | 21.42億 USD | 22.52億 USD |
| 売上原価 | 7.99億 USD | 10.11億 USD | 7.32億 USD | 7.57億 USD | 8.01億 USD |
| 粗利益 | 12.91億 USD | 9.67億 USD | 12.34億 USD | 13.85億 USD | 14.51億 USD |
| 研究開発 | 1.88億 USD | 1.93億 USD | 1.99億 USD | 1.9億 USD | 1.9億 USD |
| 販売・一般管理 | 5.84億 USD | 5.64億 USD | 5.79億 USD | 6.04億 USD | 5.84億 USD |
| 営業費用 | 7.71億 USD | 8.7億 USD | 8.24億 USD | 8.53億 USD | 8.21億 USD |
| 受取利息 | 6432万 USD | 6801.6万 USD | 7899.2万 USD | 3275.7万 USD | 955.5万 USD |
| 支払利息 | 3325.6万 USD | 4384.1万 USD | 5341万 USD | 5835.7万 USD | 5447.7万 USD |
| 減価償却費と償却費 | 1.94億 USD | 2.03億 USD | 2.05億 USD | 2.08億 USD | 2.15億 USD |
| 営業利益 | 5.2億 USD | 9771.1万 USD | 4.1億 USD | 5.31億 USD | 6.3億 USD |
| 純利益 | 4.25億 USD | 8359.1万 USD | 3.41億 USD | 4.23億 USD | 5.13億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$43.01
下落余地(5.22%)| 種別 | 配当落ち日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
配当 | 2026年7月7日 | $0.35Semi-Annual | 2026年7月7日 | 2026年7月14日 |
配当 | 2026年1月8日 | $2.29Semi-Annual | 2026年1月8日 | — |
配当 | 2025年7月2日 | $0.25Semi-Annual | 2025年7月2日 | 2025年7月10日 |
配当 | 2025年1月29日 | $1.26Annual | 2025年1月29日 | 2025年1月29日 |
配当 | 2024年1月30日 | $1.28Special | 2024年1月31日 | 2024年1月31日 |
配当 | 2017年1月25日 | $1.04Irregular | 2017年1月26日 | — |
配当落ち 2026年7月7日
$0.35
Semi-Annual
2026年7月7日基準 · 支払日 2026年7月14日
配当落ち 2026年1月8日
$2.29
Semi-Annual
2026年1月8日基準
配当落ち 2025年7月2日
$0.25
Semi-Annual
2025年7月2日基準 · 支払日 2025年7月10日
配当落ち 2025年1月29日
$1.26
Annual
2025年1月29日基準 · 支払日 2025年1月29日
配当落ち 2024年1月30日
$1.28
Special
2024年1月31日基準 · 支払日 2024年1月31日
配当落ち 2017年1月25日
$1.04
Irregular
2017年1月26日基準
この株式へのエクスポージャーを報告している上場投資信託です。
iShares Russell Mid-Cap ETFIWR3812.17万0.07%567.65億 USD0.18%$109.82+0.87%
iShares Russell 1000 Value ETFIWD2040.74万0.02%829.47億 USD0.18%$253.54+0.61%
First Trust Health Care AlphaDEX FundFXH1543.23万1.39%11.13億 USD0.61%$130.15+1.37%
iShares Russell Mid-Cap Value ETFIWS1392.89万0.09%153.1億 USD0.23%$164.89+0.61%
Invesco Biotechnology & Genome ETFPBE1217.15万2.88%4.22億 USD0.59%$97.065+2.98%
iShares Systematic Alternatives Active ETFIALT633.27万0.08%75.64億 USD0.99%$30.09+0.60%
iShares Russell 1000 ETFIWB631.6万0.01%496.24億 USD0.15%$425.33+0.67%
iShares U.S. Healthcare ETFIYH596.76万0.15%41.76億 USD0.37%$72.14+1.72%
iShares Russell Mid-Cap ETFIWR
iShares Russell 1000 Value ETFIWD
First Trust Health Care AlphaDEX FundFXH
iShares Russell Mid-Cap Value ETFIWS
Invesco Biotechnology & Genome ETFPBE
iShares Systematic Alternatives Active ETFIALT
iShares Russell 1000 ETFIWB
iShares U.S. Healthcare ETFIYHAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。